Neuromyelitis Optica (NMO) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Neuromyelitis optica (NMO), also known as Devic syndrome, manifests as a clinical syndrome characterized by recurrent acute optic neuritis and transverse myelitis. In the majority of patients, NMO is driven by pathogenic serum IgG autoantibodies targeting aquaporin 4 (AQP4), which happens to be the most prevalent water-channel protein within the central nervous system (CNS). In more than 80% of cases, NMO is a result of the presence of pathogenic IgG autoantibodies directed against aquaporin 4 (AQP4-IgG), the predominant water channel protein in the CNS. Roughly 10–40% of individuals diagnosed with NMO who do not possess AQP4-IgG instead have IgG autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG-IgG). Notably, MOG-IgG is also detected in a subgroup of patients, primarily children, with acute disseminated encephalomyelitis (ADEM). The most prominent risk factor for NMO is gender, with a strong association observed in females, particularly in those with AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD). NMO can manifest at any age, with a median age at onset of 40 years for AQP4-IgG-positive patients and 31 years for MOG-IgG-positive patients. It is more prevalent in women than men, especially among those with AQP4-IgG (male-to-female ratio ranging from 1:9 to 1:10). This gender discrepancy is less pronounced in patients with seronegative NMO and those with MOG-IgG. The management and treatment of NMO/NMOSD involve various strategies, including addressing symptoms, managing acute relapses, and implementing long-term maintenance through immunosuppressive therapies. Symptomatic therapy encompasses the treatment of pain, fatigue, bowel/bladder issues, cognitive deficits, sexual dysfunction, and muscle spasms. Acute relapse management includes corticosteroid therapy and plasma exchange (PLEX). However, approximately 90% of patients may eventually experience relapses and/or develop permanent disabilities. Consequently, long-term symptom management with immunotherapy is crucial in NMO/NMOSD due to its association with relapse-related disability, unfavorable prognosis, and high mortality risk in untreated individuals. The FDA has granted approval to three drugs for NMO relapse treatment in adults: Eculizumab (Soliris, Elizaria), Satralizumab (Enspryng), and Inebilizumab (Uplizna).

 

Thelansis’s “Neuromyelitis Optica (NMO) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuromyelitis Optica (NMO) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Neuromyelitis Optica (NMO) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Neuromyelitis Optica (NMO) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Neuromyelitis Optica (NMO) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Neuromyelitis Optica (NMO), Neuromyelitis Optica (NMO) market outlook, Neuromyelitis Optica (NMO) competitive landscape, Neuromyelitis Optica (NMO) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more